Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
busulfan + cyclophosphamide + ruxolitinib + decitabine
- Development stage
- Unknown
- Lead developer
- Chinese PLA General Hospital
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination conditioning regimen used primarily before allogeneic stem cell transplantation for high-risk acute myeloid leukemia (AML) and other hematological malignancies. This regimen combines two alkylating agents (busulfan and cyclophosphamide) with a JAK1/2 inhibitor (ruxolitinib) and a hypomethylating agent (decitabine) to potentially reduce relapse rates and improve outcomes in high-risk patients.
- Other names
- modified busulfan-cyclophosphamide (mBu/Cy) conditioning with ruxolitinib and decitabine
02
Targets
Beyond the preview
Go deeper on busulfan + cyclophosphamide + ruxolitinib + decitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on busulfan + cyclophosphamide + ruxolitinib + decitabine.